West Pharmaceutical Services to Release Q1 2026 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy WST?
Source: PRnewswire
- Earnings Release Schedule: West Pharmaceutical Services plans to announce its Q1 2026 financial results before the market opens on April 23, 2026, which is expected to provide investors with critical insights into business expectations and financial performance.
- Conference Call Details: The company will hold a conference call at 8:00 a.m. Eastern Time on the same day to discuss the financial results, requiring participants to register in advance to receive a dial-in number and unique PIN, thereby enhancing investor engagement.
- Investor Resources: On the day of the call, a slide presentation will be made available on the company's investor website, and a replay of the webcast will be accessible for approximately 90 days post-event, ensuring investors can access relevant information at their convenience and improving transparency.
- Company Background: West Pharmaceutical Services is a global leader in injectable drug solutions, generating $3.07 billion in net sales for fiscal year 2025, with over 10,000 employees supporting the delivery of more than 41 billion components and devices annually, showcasing a strong market position and operational capability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WST
Wall Street analysts forecast WST stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 259.350
Low
285.00
Averages
348.70
High
375.00
Current: 259.350
Low
285.00
Averages
348.70
High
375.00
About WST
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
West Pharmaceutical Services to Release Q1 2026 Financial Results
- Earnings Release Schedule: West Pharmaceutical Services plans to announce its Q1 2026 financial results before the market opens on April 23, 2026, which is expected to provide investors with critical insights into business expectations and financial performance.
- Conference Call Details: The company will hold a conference call at 8:00 a.m. Eastern Time on the same day to discuss the financial results, requiring participants to register in advance to receive a dial-in number and unique PIN, thereby enhancing investor engagement.
- Investor Resources: On the day of the call, a slide presentation will be made available on the company's investor website, and a replay of the webcast will be accessible for approximately 90 days post-event, ensuring investors can access relevant information at their convenience and improving transparency.
- Company Background: West Pharmaceutical Services is a global leader in injectable drug solutions, generating $3.07 billion in net sales for fiscal year 2025, with over 10,000 employees supporting the delivery of more than 41 billion components and devices annually, showcasing a strong market position and operational capability.
See More
SiriusXM and Marvell Options Trading Activity Surges
- SiriusXM Options Volume: As of today, SiriusXM Holdings Inc has seen options trading volume of 19,008 contracts, representing approximately 1.9 million shares, which constitutes 50.3% of its average daily trading volume over the past month, indicating a significant increase in market interest.
- High Volume Put Options: Within SiriusXM, the $23 strike put option has been particularly active, with 5,496 contracts traded today, equating to about 549,600 shares, reflecting investor expectations of potential downward price movement, which could influence market sentiment.
- Marvell Options Volume: Concurrently, Marvell Technology Inc has recorded options trading volume of 128,589 contracts, representing approximately 12.9 million shares, or 49.4% of its average daily trading volume over the past month, showcasing strong investor interest in the company.
- High Volume Call Options: For Marvell, the $115 strike call option has seen 9,401 contracts traded, amounting to approximately 940,100 shares, indicating market confidence in the stock's future price increase, which may drive its stock price higher.
See More
West Pharmaceutical Expands Facility in Dublin to Meet Growing Demand
- New Facility Expansion: West Pharmaceutical has opened a new 165,000 square foot building in Damastown, Dublin, significantly enhancing its contract services to meet global demand for high-volume treatments such as diabetes and obesity.
- Enhanced Drug Handling Capabilities: This expansion not only boosts component molding, device assembly, and packaging capabilities but also adds advanced automation and commercial-scale drug handling, ensuring support for complex injectable drug delivery systems.
- Integrated Service Platform: The new facility is part of West Vantage™, which provides a single-source solution spanning product conceptualization, development, manufacturing, assembly, packaging, validation, analytical testing, and regulatory support, accelerating time to market for pharmaceuticals.
- Market Leadership: West Pharmaceutical achieved $3.07 billion in net sales in fiscal year 2025, solidifying its position as a leading provider of high-quality injectable solutions with over 10,000 employees and a global network of 50 sites.
See More
West Pharmaceutical Expands Facility in Dublin to Meet Global Demand
- Facility Expansion: West Pharmaceutical has opened a new 165,000 square foot facility in Damastown, Dublin, significantly enhancing its contract services to meet global demand for high-volume injectable treatments, particularly for diabetes and obesity.
- Increased Global Capacity: This expansion boosts West's drug handling capabilities for high-volume injectable therapies, including next-generation GLP-1 treatments, reinforcing its role as a critical partner in ensuring patient access to these essential medicines.
- Integrated Service Capabilities: The new facility expands capabilities beyond component molding, device assembly, and packaging to include advanced automation and enhanced drug-handling capabilities at commercial scale, addressing the growing demand for complex injectable drug delivery systems.
- Accelerated Market Access: Through West Vantage™, the company provides a comprehensive single-source solution for pharmaceutical and biotechnology partners, spanning product conceptualization to market, helping clients accelerate time to market and ensuring the global supply of life-enhancing and life-saving therapies.
See More
McKesson Reports Strong Q3 Fiscal 2026 Results Driven by Specialty Growth
- Core Business Growth: McKesson achieved an 11% revenue growth and a 13% operating profit growth in Q3, primarily driven by broad momentum in oncology, multispecialty, and pharmaceutical distribution, showcasing the company's strong competitiveness in high-growth healthcare sectors.
- Specialty Drug Boost: Revenues from GLP-1 therapies rose 26% year-over-year to $14 billion, indicating the company's significant advantage in distributing high-cost, complex therapies, which enhances margins and market share.
- Acquisition-Driven Profitability: The oncology and multispecialty segment saw a 57% operating profit growth, supported by acquisitions like PRISM Vision and Florida Cancer Specialists, reinforcing McKesson's strategic position in high-margin service platforms.
- Medical-Surgical Segment Challenges: The Medical-Surgical segment reported only 1% revenue growth and a 10% decline in operating profit, reflecting its sensitivity to external factors, which may limit overall growth potential and impact consolidated performance.
See More
Analysis of Risks in Overvalued Stocks
- Keysight Stock Risks: Keysight (NYSE:KEYS) has shown only 3.1% annual revenue growth over the past two years, which is below industry peers, and declining earnings per share raises investor concerns; with a current stock price of $286.50 and a forward P/E of 31.4x, it indicates significant overvaluation risks.
- Moog Stock Caution: Moog (NYSE:MOG.A) has experienced only 4.9% annual revenue growth over the last five years, while increasing capital intensity has led to a 6.6 percentage point drop in free cash flow margin; trading at $308.25 per share with a forward P/E of 32.9x reflects management's struggles in finding profitable growth opportunities.
- West Pharmaceutical Services Risks: West Pharmaceutical Services (NYSE:WST) has seen a mere 2.1% annual revenue growth over the last two years, with a 6.7 percentage point decrease in adjusted operating margin, and a stock price of $238.92 implies a forward P/E of 29.9x, indicating weakening profitability.
- Identifying Market Opportunities: Despite the risks associated with these overvalued stocks, StockStory's list of high-quality stocks demonstrates robust revenue growth and cash flow, assisting investors in identifying potential market winners.
See More
West Pharmaceutical Services to Release Q1 2026 Financial Results
- Earnings Release Schedule: West Pharmaceutical Services plans to announce its Q1 2026 financial results before the market opens on April 23, 2026, which is expected to provide investors with critical insights into business expectations and financial performance.
- Conference Call Details: The company will hold a conference call at 8:00 a.m. Eastern Time on the same day to discuss the financial results, requiring participants to register in advance to receive a dial-in number and unique PIN, thereby enhancing investor engagement.
- Investor Resources: On the day of the call, a slide presentation will be made available on the company's investor website, and a replay of the webcast will be accessible for approximately 90 days post-event, ensuring investors can access relevant information at their convenience and improving transparency.
- Company Background: West Pharmaceutical Services is a global leader in injectable drug solutions, generating $3.07 billion in net sales for fiscal year 2025, with over 10,000 employees supporting the delivery of more than 41 billion components and devices annually, showcasing a strong market position and operational capability.
See More
SiriusXM and Marvell Options Trading Activity Surges
- SiriusXM Options Volume: As of today, SiriusXM Holdings Inc has seen options trading volume of 19,008 contracts, representing approximately 1.9 million shares, which constitutes 50.3% of its average daily trading volume over the past month, indicating a significant increase in market interest.
- High Volume Put Options: Within SiriusXM, the $23 strike put option has been particularly active, with 5,496 contracts traded today, equating to about 549,600 shares, reflecting investor expectations of potential downward price movement, which could influence market sentiment.
- Marvell Options Volume: Concurrently, Marvell Technology Inc has recorded options trading volume of 128,589 contracts, representing approximately 12.9 million shares, or 49.4% of its average daily trading volume over the past month, showcasing strong investor interest in the company.
- High Volume Call Options: For Marvell, the $115 strike call option has seen 9,401 contracts traded, amounting to approximately 940,100 shares, indicating market confidence in the stock's future price increase, which may drive its stock price higher.
See More
West Pharmaceutical Expands Facility in Dublin to Meet Growing Demand
- New Facility Expansion: West Pharmaceutical has opened a new 165,000 square foot building in Damastown, Dublin, significantly enhancing its contract services to meet global demand for high-volume treatments such as diabetes and obesity.
- Enhanced Drug Handling Capabilities: This expansion not only boosts component molding, device assembly, and packaging capabilities but also adds advanced automation and commercial-scale drug handling, ensuring support for complex injectable drug delivery systems.
- Integrated Service Platform: The new facility is part of West Vantage™, which provides a single-source solution spanning product conceptualization, development, manufacturing, assembly, packaging, validation, analytical testing, and regulatory support, accelerating time to market for pharmaceuticals.
- Market Leadership: West Pharmaceutical achieved $3.07 billion in net sales in fiscal year 2025, solidifying its position as a leading provider of high-quality injectable solutions with over 10,000 employees and a global network of 50 sites.
See More
West Pharmaceutical Expands Facility in Dublin to Meet Global Demand
- Facility Expansion: West Pharmaceutical has opened a new 165,000 square foot facility in Damastown, Dublin, significantly enhancing its contract services to meet global demand for high-volume injectable treatments, particularly for diabetes and obesity.
- Increased Global Capacity: This expansion boosts West's drug handling capabilities for high-volume injectable therapies, including next-generation GLP-1 treatments, reinforcing its role as a critical partner in ensuring patient access to these essential medicines.
- Integrated Service Capabilities: The new facility expands capabilities beyond component molding, device assembly, and packaging to include advanced automation and enhanced drug-handling capabilities at commercial scale, addressing the growing demand for complex injectable drug delivery systems.
- Accelerated Market Access: Through West Vantage™, the company provides a comprehensive single-source solution for pharmaceutical and biotechnology partners, spanning product conceptualization to market, helping clients accelerate time to market and ensuring the global supply of life-enhancing and life-saving therapies.
See More
McKesson Reports Strong Q3 Fiscal 2026 Results Driven by Specialty Growth
- Core Business Growth: McKesson achieved an 11% revenue growth and a 13% operating profit growth in Q3, primarily driven by broad momentum in oncology, multispecialty, and pharmaceutical distribution, showcasing the company's strong competitiveness in high-growth healthcare sectors.
- Specialty Drug Boost: Revenues from GLP-1 therapies rose 26% year-over-year to $14 billion, indicating the company's significant advantage in distributing high-cost, complex therapies, which enhances margins and market share.
- Acquisition-Driven Profitability: The oncology and multispecialty segment saw a 57% operating profit growth, supported by acquisitions like PRISM Vision and Florida Cancer Specialists, reinforcing McKesson's strategic position in high-margin service platforms.
- Medical-Surgical Segment Challenges: The Medical-Surgical segment reported only 1% revenue growth and a 10% decline in operating profit, reflecting its sensitivity to external factors, which may limit overall growth potential and impact consolidated performance.
See More
Analysis of Risks in Overvalued Stocks
- Keysight Stock Risks: Keysight (NYSE:KEYS) has shown only 3.1% annual revenue growth over the past two years, which is below industry peers, and declining earnings per share raises investor concerns; with a current stock price of $286.50 and a forward P/E of 31.4x, it indicates significant overvaluation risks.
- Moog Stock Caution: Moog (NYSE:MOG.A) has experienced only 4.9% annual revenue growth over the last five years, while increasing capital intensity has led to a 6.6 percentage point drop in free cash flow margin; trading at $308.25 per share with a forward P/E of 32.9x reflects management's struggles in finding profitable growth opportunities.
- West Pharmaceutical Services Risks: West Pharmaceutical Services (NYSE:WST) has seen a mere 2.1% annual revenue growth over the last two years, with a 6.7 percentage point decrease in adjusted operating margin, and a stock price of $238.92 implies a forward P/E of 29.9x, indicating weakening profitability.
- Identifying Market Opportunities: Despite the risks associated with these overvalued stocks, StockStory's list of high-quality stocks demonstrates robust revenue growth and cash flow, assisting investors in identifying potential market winners.
See More
